These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28376145)

  • 1. Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.
    Kawakami M; Mustachio LM; Rodriguez-Canales J; Mino B; Roszik J; Tong P; Wang J; Lee JJ; Myung JH; Heymach JV; Johnson FM; Hong S; Zheng L; Hu S; Villalobos PA; Behrens C; Wistuba I; Freemantle S; Liu X; Dmitrovsky E
    J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110.
    Hu S; Danilov AV; Godek K; Orr B; Tafe LJ; Rodriguez-Canales J; Behrens C; Mino B; Moran CA; Memoli VA; Mustachio LM; Galimberti F; Ravi S; DeCastro A; Lu Y; Sekula D; Andrew AS; Wistuba II; Freemantle S; Compton DA; Dmitrovsky E
    Cancer Res; 2015 May; 75(10):2029-38. PubMed ID: 25808870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown.
    Hu S; Lu Y; Orr B; Godek K; Mustachio LM; Kawakami M; Sekula D; Compton DA; Freemantle S; Dmitrovsky E
    Mol Cancer Ther; 2015 Nov; 14(11):2576-85. PubMed ID: 26304236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.
    Danilov AV; Hu S; Orr B; Godek K; Mustachio LM; Sekula D; Liu X; Kawakami M; Johnson FM; Compton DA; Freemantle SJ; Dmitrovsky E
    Mol Cancer Ther; 2016 Nov; 15(11):2758-2766. PubMed ID: 27550941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers.
    Kawakami M; Mustachio LM; Chen Y; Chen Z; Liu X; Wei CH; Roszik J; Kittai AS; Danilov AV; Zhang X; Fang B; Wang J; Heymach JV; Tyutyunyk-Massey L; Freemantle SJ; Kurie JM; Liu X; Dmitrovsky E
    Mol Cancer Ther; 2021 Mar; 20(3):477-489. PubMed ID: 33277443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.
    Galimberti F; Thompson SL; Liu X; Li H; Memoli V; Green SR; DiRenzo J; Greninger P; Sharma SV; Settleman J; Compton DA; Dmitrovsky E
    Clin Cancer Res; 2010 Jan; 16(1):109-20. PubMed ID: 20028770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK2 inhibition disorders centrosome stoichiometry and alters cellular outcomes in aneuploid cancer cells.
    Chen Z; Liu X; Kawakami M; Liu X; Baker A; Bhatawadekar A; Tyutyunyk-Massey L; Narayan K; Dmitrovsky E
    Cancer Biol Ther; 2023 Dec; 24(1):2279241. PubMed ID: 38031910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers.
    Kawakami M; Mustachio LM; Liu X; Dmitrovsky E
    Mol Cancer Ther; 2018 Apr; 17(4):724-731. PubMed ID: 29559545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.
    Wilson SC; Atrash B; Barlow C; Eccles S; Fischer PM; Hayes A; Kelland L; Jackson W; Jarman M; Mirza A; Moreno J; Nutley BP; Raynaud FI; Sheldrake P; Walton M; Westwood R; Whittaker S; Workman P; McDonald E
    Bioorg Med Chem; 2011 Nov; 19(22):6949-65. PubMed ID: 21982796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRIGGERING ANAPHASE CATASTROPHE TO COMBAT ANEUPLOID CANCERS.
    Dmitrovsky E; Kawakami M; Liu XI; Freemantle SJ; Kurie JM
    Trans Am Clin Climatol Assoc; 2020; 131():82-94. PubMed ID: 32675848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of UGT1A1 and CYP2B6 by an antimitogenic factor in HepG2 cells is mediated through suppression of cyclin-dependent kinase 2 activity: cell cycle-dependent expression.
    Sugatani J; Osabe M; Kurosawa M; Kitamura N; Ikari A; Miwa M
    Drug Metab Dispos; 2010 Jan; 38(1):177-86. PubMed ID: 19797611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
    Coley HM; Shotton CF; Kokkinos MI; Thomas H
    Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
    Whittaker SR; Walton MI; Garrett MD; Workman P
    Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer.
    Jiang X; Zhang C; Li W; Jiang D; Wei Z; Lv M; Xie X; Sun X
    Oncol Rep; 2019 Mar; 41(3):1949-1959. PubMed ID: 30569123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy.
    Zheng L; Chen Z; Kawakami M; Chen Y; Roszik J; Mustachio LM; Kurie JM; Villalobos P; Lu W; Behrens C; Mino B; Solis LM; Silvester J; Thu KL; Cescon DW; Rodriguez-Canales J; Wistuba II; Mak TW; Liu X; Dmitrovsky E
    Mol Cancer Ther; 2019 Oct; 18(10):1775-1786. PubMed ID: 31358662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer.
    Somarelli JA; Roghani RS; Moghaddam AS; Thomas BC; Rupprecht G; Ware KE; Altunel E; Mantyh JB; Kim SY; McCall SJ; Shen X; Mantyh CR; Hsu DS
    Mol Cancer Ther; 2020 Dec; 19(12):2516-2527. PubMed ID: 33158998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Equol inhibits proliferation of human gastric carcinoma cells via modulating Akt pathway.
    Yang ZP; Zhao Y; Huang F; Chen J; Yao YH; Li J; Wu XN
    World J Gastroenterol; 2015 Sep; 21(36):10385-99. PubMed ID: 26420965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
    Cai D; Byth KF; Shapiro GI
    Cancer Res; 2006 Jan; 66(1):435-44. PubMed ID: 16397259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.